- Home
- VRTX vs PLTR Comparison
VRTX vs PLTR Comparison
Compare VRTX & PLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- PLTR
- Stock Information
- Founded
- VRTX 1989
- PLTR 2003
- Country
- VRTX United States
- PLTR United States
- Employees
- VRTX N/A
- PLTR N/A
- Industry
- VRTX EDP Services
- PLTR Retail: Computer Software & Peripheral Equipment
- Sector
- VRTX Technology
- PLTR Technology
- Exchange
- VRTX Nasdaq
- PLTR Nasdaq
- Market Cap
- VRTX 104.8B
- PLTR 92.7B
- IPO Year
- VRTX 1991
- PLTR 2020
- Fundamental
- Price
- VRTX $422.00
- PLTR $71.77
- Analyst Decision
- VRTX Buy
- PLTR Hold
- Analyst Count
- VRTX 30
- PLTR 16
- Target Price
- VRTX $503.92
- PLTR $41.36
- AVG Volume (30 Days)
- VRTX 2.1M
- PLTR 84.7M
- Earning Date
- VRTX 02-03-2025
- PLTR 02-03-2025
- Dividend Yield
- VRTX N/A
- PLTR N/A
- EPS Growth
- VRTX N/A
- PLTR 190.66
- EPS
- VRTX N/A
- PLTR 0.20
- Revenue
- VRTX $10,625,800,000.00
- PLTR $2,646,338,000.00
- Revenue This Year
- VRTX $12.56
- PLTR $28.81
- Revenue Next Year
- VRTX $8.34
- PLTR $24.46
- P/E Ratio
- VRTX N/A
- PLTR $343.06
- Revenue Growth
- VRTX 10.06
- PLTR 24.52
- 52 Week Low
- VRTX $377.85
- PLTR $16.03
- 52 Week High
- VRTX $519.88
- PLTR $84.80
- Technical
- Relative Strength Index (RSI)
- VRTX 48.34
- PLTR 51.37
- Support Level
- VRTX $397.25
- PLTR $63.40
- Resistance Level
- VRTX $425.49
- PLTR $80.06
- Average True Range (ATR)
- VRTX 8.24
- PLTR 3.59
- MACD
- VRTX 3.71
- PLTR -1.20
- Stochastic Oscillator
- VRTX 79.84
- PLTR 45.00
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About PLTR Palantir Technologies Inc.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. The Denver-based company was founded in 2003 and went public in 2020.